Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Vacino Biotech Co. Ltd. is currently prosecuting patent applications in the Biotechnology & Pharmaceuticals technology area. The portfolio data reveals 1 pending office action. This matter is handled by 1 distinct examiner. The prosecution is also limited to 1 distinct art unit. This indicates a very focused legal landscape where the company's current filings are reviewed by a single official in a single technical department.
The busiest examiner for the company is PERSONS, JENNA L, who holds 1 pending office action. This count is identical to the 1 total pending office action for the portfolio. Practitioners should focus their efforts on the specific preferences of PERSONS, JENNA L. Because the number of distinct examiners is 1 and the number of distinct art units is 1, there is no diversity in the current review process. The 1 pending action represents the entire active workload, making the interaction with PERSONS, JENNA L critical for the portfolio's success.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PERSONS, JENNA L | 1 | 50.8% | +61.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18502329 | OLIGONUCLEOTIDE THERAPEUTICS AND APPLICATION THEREOF | PERSONS, JENNA L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18502329 | OLIGONUCLEOTIDE THERAPEUTICS AND APPLICATION THEREOF | PERSONS, JENNA L | — |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18502329 | OLIGONUCLEOTIDE THERAPEUTICS AND APPLICATION THEREOF | PERSONS, JENNA L | 1637 | §102§112Other | Non-Final OA | — | Pending | Nov 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVacino Biotech Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jenna L Persons has the most, with 1 of Vacino Biotech Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.